iOmx Therapeutics raises EUR 65 million in Series B round

6. October 2021
|In Portfolio News
|By eazee-designstudio

iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the closing of a Series B round totaling EUR 65 million.